Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM336 in Moderate to Severe Autoimmune Blistering Diseases (Phase I/II)
ChiCTR2500095272Phase 2Not yet recruiting
- Sponsor
- Shandong First Medical University Affiliated Dermatology Hospital
- Start
- Jan 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of gamgertamig in pemphigus vulgaris (PV) and Bullous Pemphigoid (BP) (2 arms), sponsored by Shandong First Medical University Affiliated Dermatology Hospital. Primary endpoint: Complete remission at 24 weeks with minimal-dose prednisone (or equivalent). Planned start Jan 2025; status: not yet recruiting.
02
Drugs
gamgertamig
03
Conditions
pemphigus vulgaris (PV)Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on ChiCTR2500095272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095272.